NuGEN Technologies, Inc. Selected for Next Stage of the Framingham Heart Study at the National Heart, Lung, and Blood Institute

SAN CARLOS, Calif.--(BUSINESS WIRE)--NuGENĀ® Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

Back to news